Tags

Type your tag names separated by a space and hit enter

Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs.
Expert Rev Clin Pharmacol 2020; 13(1):53-64ER

Abstract

Introduction: Obesity poses a significant increase in morbidity and mortality and thus five anti-obesity drugs have been approved currently by US FDA. Several phase 3 trials have shown a significant improvement in cardio-metabolic profile including significant weight reduction with these agents compared to placebo.Areas covered: We systematically searched the database of PubMed, Embase, The Cochrane Library and The ClinicalTrials.gov up to 30 September 2019 and retrieved all the randomized controlled trials (RCTs) that were conducted with these five drugs for ≥1 year and explicitly reported their efficacy versus placebo. Subsequently, we have conducted the meta-analysis to primarily study the effect of these anti-obesity drugs on weight reduction. We additionally reviewed the effect of these drugs on other cardio-metabolic parameters including key adverse events.Expert opinion: This meta-analysis finds a significant reduction in body weight with orlistat (N = 10,435; ∆ -3.07 Kg, 95% CI, -3.76 to -2.37), phentermine plus topiramate (N = 2985; ∆ -9.77 Kg; 95% CI, -11.73 to -7.81), lorcaserin (N = 16,856; ∆ -3.08 Kg; 95% CI, -3.49 to -2.66), naltrexone plus bupropion (N = 3239; ∆ -4.39 Kg; 95% CI, -5.05 to -3.72) and liraglutide (N = 4978; ∆ -5.25 Kg; 95% CI, -6.17 to -4.32), compared to placebo (all p < 0.00001).

Authors+Show Affiliations

Department of Endocrinology, G.D Hospital & Diabetes Institute, Kolkata, India.Department of Gynecology & Obstetrics, G. D Hospital & Diabetes Institute, Kolkata, India.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31770497

Citation

Singh, Awadhesh Kumar, and Ritu Singh. "Pharmacotherapy in Obesity: a Systematic Review and Meta-analysis of Randomized Controlled Trials of Anti-obesity Drugs." Expert Review of Clinical Pharmacology, vol. 13, no. 1, 2020, pp. 53-64.
Singh AK, Singh R. Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs. Expert Rev Clin Pharmacol. 2020;13(1):53-64.
Singh, A. K., & Singh, R. (2020). Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs. Expert Review of Clinical Pharmacology, 13(1), pp. 53-64. doi:10.1080/17512433.2020.1698291.
Singh AK, Singh R. Pharmacotherapy in Obesity: a Systematic Review and Meta-analysis of Randomized Controlled Trials of Anti-obesity Drugs. Expert Rev Clin Pharmacol. 2020;13(1):53-64. PubMed PMID: 31770497.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs. AU - Singh,Awadhesh Kumar, AU - Singh,Ritu, Y1 - 2019/12/22/ PY - 2019/11/27/pubmed PY - 2019/11/27/medline PY - 2019/11/27/entrez KW - Obesity KW - anti-obesity drugs KW - liraglutide 3.0 mg KW - lorcaserin KW - naltrexone plus bupropion KW - orlistat KW - phentermine plus topiramate SP - 53 EP - 64 JF - Expert review of clinical pharmacology JO - Expert Rev Clin Pharmacol VL - 13 IS - 1 N2 - Introduction: Obesity poses a significant increase in morbidity and mortality and thus five anti-obesity drugs have been approved currently by US FDA. Several phase 3 trials have shown a significant improvement in cardio-metabolic profile including significant weight reduction with these agents compared to placebo.Areas covered: We systematically searched the database of PubMed, Embase, The Cochrane Library and The ClinicalTrials.gov up to 30 September 2019 and retrieved all the randomized controlled trials (RCTs) that were conducted with these five drugs for ≥1 year and explicitly reported their efficacy versus placebo. Subsequently, we have conducted the meta-analysis to primarily study the effect of these anti-obesity drugs on weight reduction. We additionally reviewed the effect of these drugs on other cardio-metabolic parameters including key adverse events.Expert opinion: This meta-analysis finds a significant reduction in body weight with orlistat (N = 10,435; ∆ -3.07 Kg, 95% CI, -3.76 to -2.37), phentermine plus topiramate (N = 2985; ∆ -9.77 Kg; 95% CI, -11.73 to -7.81), lorcaserin (N = 16,856; ∆ -3.08 Kg; 95% CI, -3.49 to -2.66), naltrexone plus bupropion (N = 3239; ∆ -4.39 Kg; 95% CI, -5.05 to -3.72) and liraglutide (N = 4978; ∆ -5.25 Kg; 95% CI, -6.17 to -4.32), compared to placebo (all p < 0.00001). SN - 1751-2441 UR - https://www.unboundmedicine.com/medline/citation/31770497/Pharmacotherapy_in_obesity:_a_systematic_review_and_meta-analysis_of_randomized_controlled_trials_of_anti-obesity_drugs L2 - http://www.tandfonline.com/doi/full/10.1080/17512433.2020.1698291 DB - PRIME DP - Unbound Medicine ER -